The New Year started excellently for MID-Frail with the first patients being enrolled into the study. This happened in Spain where there are two active sites and three patients have been enrolled so far. With this, a crucial study milestone has been achieved. You can download the latest newsletter [1].
A special thank you to Drs Castro and Manzarbeitia, and congratulations to the team at the Hospital de Getafe. MID-Frail is also progressing in other countries, with several sites close to recruiting their first patient. The Czech Republic is leading the way with Investigator and initiation meetings completed at all trial sites. Four sites are now actively recruiting, and six patients have been screened and found eligible; other sites areexpected to start recruitment soon .
Towards the end of last year, Néboa Zozaya and Juan Oliva from the Universidad de Castilla-La Mancha volunteered to write an instructional article for this newsletter on the economic impact of diabetes and the importance of getting an accurate estimate of the size of the costs. One of our major challenges will be to capture a thorough picture of health and social resource expenditure associated with the treatment and care of the study subjects for each of the participant countries. It will only be possible to achieve this if each of the countries involved in the MID-Frail study provides precise, detailed and up-to-date information on resource use, unit costs and treatment pathways. The summary article is published in the newsletter.
The manuscript describing the study protocol submitted to the journal ‘Trials’ has been published [2].
References
I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) approval for their live attenuated.
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
Advisory board meetings are often used to address perceived knowledge gaps and build consensus.
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
